Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financi...(le notes and warrants. The Company also ...),Health

Date:5/7/2008

le notes, and warrants. The Company also expects to receive an additional $5 million in gross proceeds from an additional sale of securities to the purchaser of the Series E preferred stock and 13.5% convertible senior notes prior to July 4, 2008, provided adequate shares are available for issuance of such securities at that time.

"In the second quarter we expect to see the positive financial impact of our strategy to focus resources on our late-stage development products and growing Zevalin sales. With our commercial team now in place to support Zevalin, we expect revenues to continue to increase over the next few quarters," said James A. Bianco, M.D., President and CEO of CTI. "In addition, over the last two quarters, we have been successful in cleaning up our balance sheet, retiring or exchanging approximately 74 percent of current debt and preferred securities. With the majority of the investments in OPAXIO and pixantrone behind us we look forward to the review of the MAA for OPAXIO and to final results of the pixantrone pivotal trial."

Recent Highlights

o Announced that the Company selected and received a positive opinion

from the European Medicines Agency (EMEA) on the new brand name

OPAXIO(TM) (paclitaxel poliglumex), which replaces the name XYOTAX(TM)

o Announced that the EMEA accepted for review CTI's Marketing

Authorization Application (MAA) for OPAXIO for first-line treatment of

patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern

Cooperative Oncology Group) performance status 2 (PS2)

o Announced completion of enrollment in the phase III EXTEND (PIX301)

clinical trial of pixantrone (BBR 2778) for patients with relapsed

diffuse large B-cell non-Hodgkin's lymphoma (NHL)

o Announced the appointment of Craig W. Philips, most recently Vice

President and General Manager of Bayer Healthcare Oncology, as

president of
'/>"/>

SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
5. Profarmas Gross Revenues Reached R$ 702.6 Million in the 1st Quarter 2008, a 26.5% Growth Over the Same Period Last Year
6. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. MEDRAD(R) Revenues Grow 10 Percent in 2007
9. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
10. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
11. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent